Joint Pain Injections - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Joint pain injections market size in 2026 is estimated at USD 6.43 billion, growing from 2025 value of USD 5.99 billion with 2031 projections showing USD 9.16 billion, growing at 7.35% CAGR over 2026-2031. This report is Segmented by Injection Type (Steroid Joint Injections, Hyaluronic Acid Injections, and More), Injection Cycle (Single-Cycle, Three-Cycle, Five-Cycle), Application (Knee & Ankle, Shoulder & Elbow, and More), End User (Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Joint Pain Injections Market Trends and Insights

Increasing Osteoarthritis Incidence and Aging Population

Global osteoarthritis cases among people aged 15-64 exerting direct pressure on payers to finance minimally invasive interventions that keep working adults productive. Japan sits at the high end of prevalence with 12,610.12 cases per 100,000, an indicator of treatment demand across industrialized Asia. Post-menopausal women are driving incremental volume: nearly one-half are projected to develop osteoarthritis by 2045. These dynamics create a long-duration runway for injection therapies that defer or avoid joint replacement and maintain labor participation.

Accelerated Uptake of Single-Dose Viscosupplementation (HA)

Single-injection HA protocols cut follow-up visits while matching the efficacy of multi-injection regimens, reducing system utilization and patient travel costs. Analysis of 150,000 Korean beneficiaries showed a 44% lower total knee arthroplasty risk after single doses versus untreated cohorts, bolstering payer confidence. Industrial response is robust; BD lifted prefillable-syringe output sevenfold to satisfy anticipated demand. The operational win for providers fewer appointments has accelerated formulary placement in the United States, Germany and Japan, setting a medium-term positive arc for the joint pain injections market.

High Patient Out-of-Pocket Costs in Uninsured Segments

Coverage denials for viscosupplementation based on contested clinical value have forced some US patients to absorb the full USD 1,100-USD 1,800 per injection episode. Cigna still classifies orthopedic stem-cell therapies as “not medically necessary,” creating uneven benefit structures that suppress uptake. Internationally, many emerging-market payers reimburse surgery but not biologic injections, limiting access despite clinical need. Until definitive cost-effectiveness data influence public insurance rule-making, out-of-pocket exposure will continue to curb uptake.

Other drivers and restraints analyzed in the detailed report include:

• Wider Payer Support for PRP and Regenerative Therapies
• Proliferation of Pain-Centric Ambulatory Surgery Centers (ASCs)
• Variability in Reimbursement and Procedural Coding

Segment Analysis

The joint pain injections market size for hyaluronic acid stood equal to 47.68% of total revenue in 2025. Long-term safety, broad payer acceptance, and rising single-dose use keep HA entrenched across knee and ankle indications. PRP revenue is forecasted for a 8.72% CAGR, gaining traction as randomized studies corroborate superior WOMAC and VAS scores at 12 months.

Combination products that merge HA with collagen tripeptides or linkers appeal to severe osteoarthritis patients and could widen choice. However, the Centers for Medicare & Medicaid Services’ 2024 non-coverage determination for placental biologics narrows near-term expansion pathways. Over the forecast window, proven efficacy endpoints and payer alignment suggest PRP will chip away at HA’s dominance without dislodging it entirely from first-line status in the joint pain injections market.

Single-cycle regimens represented 58.03% of market value in 2025 as physicians embraced the convenience of one-and-done dosing. Evidence now shows three PRP injections deliver statistically greater pain relief than a single dose, forming the rationale for a 12.12% CAGR through 2031 for this segment.

Five-cycle programs remain confined to severe cases because the incremental benefit plateaus after the third dose; consequently, payer willingness to reimburse beyond three sessions is waning. Manufacturers are therefore redesigning packaging - multi-chamber kits for three cycles - to remove compounding errors and shorten prep time, a move that reinforces the growth of mid-range dosing frequencies within the joint pain injections market.

Complete Report Scope:

• By Injection Type
  • Steroid Joint Injections
  • Hyaluronic Acid (HA) Injections
  • Platelet-Rich Plasma (PRP) Injections
  • Placental Tissue Matrix (PTM) & MSC Injections
  • Other Biologic / Combination Injections
• By Injection Cycle
  • Single-cycle
  • Three-cycle
  • Five-cycle
• By Application
  • Knee & Ankle
  • Shoulder & Elbow
  • Hip Joint
  • Spinal Facet & SI Joints
  • Other Small Joints
• By End User
  • Hospitals
  • Ambulatory Surgical Centers (ASCs)
  • Orthopedic / Pain Clinics
  • Sports Medicine Centers
  • Home-Care Settings
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America delivered 36.28% of 2025 sales, anchored by the United States where Medicare Advantage now reimburses PRP under specified CPT codes and employer MSK programs average USD 52 per member per month. Canada’s single-payer model has begun funding HA in earlier disease stages, spurring 8% procedural growth. Mexico shows latent demand but still contends with uneven device registration timelines and out-of-pocket barriers, limiting near-term uptake.

Europe benefits from synchronized Medical Device Regulation that clarifies safety benchmarks for HA syringes. Germany and France drive regional procedure volume through robust outpatient networks, while the United Kingdom’s National Health Service pilots risk-share contracts tying reimbursement to functional-outcome thresholds. Southern European countries such as Spain and Italy are scaling AI-guided ultrasound to rural clinics, boosting accessibility.

Asia-Pacific is the fastest-growing territory at 10.79% CAGR, propelled by Japan’s exceptional osteoarthritis burden and well-established imaging infrastructure. China’s National Medical Products Administration has slashed device approval timelines to 150 days, accelerating market entry for single-dose HA brands. Australia, India and South Korea invest heavily in ASC construction, mirroring US practice patterns and unlocking procedural capacity. Rest-of-Asia markets exhibit early-adoption behavior with government-backed tele-ultrasound programs that may compress the diffusion curve for newer injection modalities.

List of Companies Covered in this Report:

• Anika Therapeutics
• Bioventus
• Ferring Pharmaceuticals
• Sanofi
• Pfizer
• Eli Lilly and Company
• Flexion Therapeutics
• Teva Pharmaceutical Industries
• Zimmer Biomet
• Seikagaku
• Arthrex
• Stryker
• Sequent Scientific
• Seaspine Holdings
• Chugai Pharma
• Sequoia Medical
• Meda AB
• LG Life Science
• Terumo
• Johnson & Johnson

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support